GLP-1 maintenance dosing: what the evidence actually supports

What's this video probably claiming?

Based on the caption replying to a question about "maintenance" options, @theprescribeddose is almost certainly walking through what happens after someone hits their weight loss goal on a GLP-1 receptor agonist. The likely claim: you can drop to a lower dose of semaglutide or tirzepatide to maintain weight loss without continuing to pay for or inject a full therapeutic dose. This is a real and reasonable question that millions of people on these medications will eventually face. The creator probably references dose reduction strategies, possibly mentions transitioning between agents, and may touch on the weight regain data that makes maintenance such a loaded topic. The disclaimer in the caption is appropriate for this kind of content, and the framing as educational suggests the creator is at least trying to stay on the right side of the prescribing line. That said, maintenance dosing claims deserve close scrutiny because the clinical picture here is genuinely complicated.

What does the science actually show?

The STEP 1 extension data is the most honest thing you can show anyone asking about GLP-1 maintenance. Wilding et al. (2022, New England Journal of Medicine) followed participants who stopped semaglutide 2.4mg after 68 weeks and found they regained two-thirds of their lost weight within one year of discontinuation. That is not a small signal. For tirzepatide, the SURMOUNT-4 trial (Aronne et al., 2024, JAMA) randomised participants who had already lost weight to either continue tirzepatide or switch to placebo. Those who continued lost an additional 5.5% body weight; those who stopped regained 14% over 52 weeks. The data for lower-dose maintenance, as in staying on the drug but dropping from 2.4mg semaglutide to 1mg or 0.5mg, is thinner. Some clinicians draw on the STEP 5 data (Garvey et al., 2022, Nature Medicine), which showed sustained weight loss at two years on full dosing, but that does not tell us what happens at reduced doses specifically.

Where does the social media noise diverge from clinical reality?

The gap between TikTok maintenance talk and actual clinical evidence is wide. Social media creators, even well-intentioned ones, tend to frame lower-dose maintenance as a proven strategy when it is largely based on clinical intuition and extrapolation rather than randomised trial data. There is no published, powered RCT showing that, say, semaglutide 0.5mg or 1mg sustains the weight lost on 2.4mg over 12 or 24 months in a general population. Creators also frequently conflate dose reduction with dose discontinuation, blur the line between compounded and brand-name semaglutide when discussing affordability-driven maintenance decisions, and underestimate how individually variable weight regain trajectories are. The SCALE Maintenance trial with liraglutide (Pi-Sunyer et al., 2015, NEJM) does provide some signal that continued pharmacotherapy beats placebo for weight maintenance, but liraglutide's inferior efficacy profile makes direct comparisons with newer agents unreliable. Dosing recommendations belong with the prescriber, not the comment section.

What should you actually know?

Weight regain after GLP-1 discontinuation is not a personal failure. It reflects the pharmacological reality that these drugs suppress appetite and alter gastric emptying through mechanisms that stop when the drug stops. If you are asking your prescriber about maintenance, the honest conversation involves several things: whether a lower dose has been trialled under supervision, what your metabolic markers look like at your current dose, whether you have comorbidities like type 2 diabetes or cardiovascular disease that justify continued full-dose therapy on clinical grounds separate from weight, and what the cost and access picture looks like long term. The FDA approval for Wegovy is for chronic weight management, meaning indefinite use is the intended model for many patients. Anyone suggesting a clean exit strategy should be citing data, not anecdote. Compounded semaglutide is not equivalent to branded Wegovy and should not be evaluated as though it is when discussing long-term maintenance planning.